Suchergebnisse - "Voorhees, Peter M"

PubPharm (20)

1

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

enthalten in: Blood cancer journal | 2024

von Callander, N. | Silbermann, R. | Kaufman, J. | +33

2

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN) : final analysis of an open-label, randomised, phase 2 trial

enthalten in: The Lancet. Haematology | 2023

von Voorhees, P. | Sborov, D. | Laubach, J. | +25

CommentIn: Lancet Haematol. 2023 Oct;10(10):e788-e789. - PMID 37793762

3

A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Bhutani, M. | Foureau, D. | Robinson, M. | +14

4

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma : Findings from the MASTER and GRIFFIN Trials

enthalten in: Transplantation and cellular therapy | 2023

von Chhabra, S. | Callander, N. | Watts, N. | +34

5

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma : Analysis of vascular thrombotic events in the GRIFFIN study

enthalten in: British journal of haematology | 2022

von Sborov, D. | Baljevic, M. | Reeves, B. | +18

6

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

enthalten in: The New England journal of medicine | 2022

von Richardson, P. | Jacobus, S. | Weller, E. | +125

CommentIn: Expert Rev Hematol. 2023 Jul-Dec;16(8):561-563. - PMID 37334674

7

A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)

enthalten in: American journal of hematology | 2021

von Voorhees, P. | Suman, V. | Tuchman, S. | +9

8

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma : long-term survival follow-up from the Phase II study O-12-M1

enthalten in: British journal of haematology | 2021

von Bringhen, S. | Voorhees, P. | Plesner, T. | +8

9

Daratumumab plus RVd for newly diagnosed multiple myeloma : final analysis of the safety run-in cohort of GRIFFIN

enthalten in: Blood advances | 2021

von Voorhees, P. | Rodriguez, C. | Reeves, B. | +10

10

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211) : primary analysis of a randomised, phase 2 trial

enthalten in: The Lancet. Haematology | 2021

von Usmani, S. | Hoering, A. | Ailawadhi, S. | +15

CommentIn: Lancet Haematol. 2021 Jan;8(1):e4-e6. - PMID 33357481